<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346657</url>
  </required_header>
  <id_info>
    <org_study_id>98030</org_study_id>
    <nct_id>NCT01346657</nct_id>
  </id_info>
  <brief_title>The Effect of LipoCol Forte® Capsules on the Pharmacokinetics of Nifedipine After Administering Single-dose Combination to Healthy Subjects</brief_title>
  <official_title>The Effect of LipoCol Forte® Capsules on the Pharmacokinetics of Nifedipine After Administering Single-dose Combination to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University WanFang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University WanFang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the effect of LipoCol Forte® Capsules on the&#xD;
      pharmacokinetics of nifedipine after administering single-dose combination to healthy&#xD;
      subjects using a 2x2 crossover design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy subjects were randomly allocated to receive a single dose of either one 5 milgram&#xD;
      (mg) nifedipine capsule or one 5 milgram (mg) nifedipine capsule plus one 600 milgram (mg)&#xD;
      red yeast rice capsule; after 7-day washout period, they received a single dose of the&#xD;
      alternative drug. The subjects were fasted at least 10 hour before dosing. The&#xD;
      investigational products were administered with 240 milliliter (mL) of water with the subject&#xD;
      in an upright position. The blood samples were collected at prior to the drug administration&#xD;
      (T0), and 0.167, 0.333, 0.500, 0.750, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 14, 16 and 24&#xD;
      hours after dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the pharmacokinetic parameters of nifedipine in healthy subjects</measure>
    <time_frame>1 week</time_frame>
    <description>Plasma concentrations of nifedipine were detected at following time: (Pre-dose (T0), and 0.167, 0.333, 0.500, 0.750, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 14, 16 and 24 hours after oral administration nifedipine capsule with or without red yeast rice capsule (LipoCol)) All pharmacokinetic parameters were determined with nifedipine concentrations by non-compartment methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of adverse event</measure>
    <time_frame>1 week</time_frame>
    <description>The incidence rate of adverse event</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Nifidipine &amp; LipoCol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifidipine &amp; LipoCol</intervention_name>
    <description>The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.</description>
    <arm_group_label>Nifidipine &amp; LipoCol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must be at the age of 20-40 years old and in good health on the basis of&#xD;
             medical history, physical examination, electrocardiogram, chest X-ray, and routine&#xD;
             laboratory evaluations.&#xD;
&#xD;
          2. Vital signs (after 3 minutes resting in a upright position) which are within the&#xD;
             following ranges:Ear body temperature between 35.0-37.5 degree celsius (°C). Systolic&#xD;
             blood pressure, 90-140 millimeters of mercury (mm Hg). Diastolic blood pressure, 50-90&#xD;
             millimeters of mercury (mm Hg). Pulse rate, 50-90 beats per minute (bpm). Fasting&#xD;
             blood glucose, &lt; 110 milligrams per deciliter (mg/dL).&#xD;
&#xD;
          3. Body weight must be above 50 kilograms (kg) and within -20 to +20% of ideal body&#xD;
             weight.&#xD;
&#xD;
          4. Able to sign informed consent prior to study.&#xD;
&#xD;
          5. Able to communicate well with the investigator and comply with the requirements of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any prescription medication within 14 days prior to dosing.&#xD;
&#xD;
          2. Use of over-the-counter medications or vitamins within 14 days prior to dosing.&#xD;
&#xD;
          3. Significant illness within 2 weeks prior to dosing.&#xD;
&#xD;
          4. Participation in any clinical investigation within 2 months prior to dosing or longer&#xD;
             than required by local regulation.&#xD;
&#xD;
          5. Donate or loss more than 500 milliliter(mL) of blood within 3 months prior to dosing.&#xD;
&#xD;
          6. Presence of cardiovascular disease.&#xD;
&#xD;
          7. Presence of gastrointestinal disease.&#xD;
&#xD;
          8. Presence of asthma or lung disease.&#xD;
&#xD;
          9. Presence of liver disease, hepatitis B, hepatitis C or liver injury as indicated by an&#xD;
             abnormal liver function profile.&#xD;
&#xD;
         10. Presence of impaired renal function.&#xD;
&#xD;
         11. Presence of neurological disease.&#xD;
&#xD;
         12. Presence of psychiatrical disease.&#xD;
&#xD;
         13. Subject is known for HIV infected.&#xD;
&#xD;
         14. A known hypersensitivity to nifedipine, lovastatin and Chinese Red Yeast Rice or their&#xD;
             analogs.&#xD;
&#xD;
         15. History of drug or alcohol abuse within 12 months prior to dosing.&#xD;
&#xD;
         16. Permanent confinement to an institution.&#xD;
&#xD;
         17. Individuals are judged by the investigator or pharmacokineticist to be undesirable as&#xD;
             subjects for other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuh-Mou Sue, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Medical University WanFang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Medical University - WanFang Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>April 27, 2011</study_first_submitted>
  <study_first_submitted_qc>May 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2011</study_first_posted>
  <last_update_submitted>May 1, 2011</last_update_submitted>
  <last_update_submitted_qc>May 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yuh-Mou Sue</name_title>
    <organization>Department of Internal Medicine, Wanfang Hospital</organization>
  </responsible_party>
  <keyword>Nifidipine</keyword>
  <keyword>red yeast rice</keyword>
  <keyword>drug-drug interaction</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

